{"url_path":"/sec/txmd/8-k/2026-08-11/item-9-01","section_key":"item-9-01","section_title":"Item 9.01 Financial Statements and Exhibits.**","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-08-11","source_url":"https://www.sec.gov/Archives/edgar/data/25743/0001213900-26-087756-index.html","accession_number":"0001213900-26-087756","cik":"0000025743","ticker":"TXMD","issuer_name":"TherapeuticsMD, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/25743/0001213900-26-087756-index.html","primary_entity_key":"0000025743","primary_entity_name":"TherapeuticsMD, Inc."},"word_count":95,"has_tables":true,"body_markdown":"**Item 9.01 Financial Statements and Exhibits.**\n\n \n\n(d) Exhibits.\n\n \n\nExhibit Index\n\n \n\nExhibit No.\n \nDescription\n\n \n \n\n99.1\n \n[Press Release from TherapeuticsMD, Inc., dated August 11, 2026, entitled “TherapeuticsMD Announces Second Quarter 2026 Financial Results.”](ea029897901ex99-1.htm)\n\n \n \n\n104\n \nCover Page Interactive Data File (the cover page tags are embedded within the Inline XBRL document).\n\n \n\n1\n\n \n\n \n\nSIGNATURES\n\n \n\nPursuant to the requirements of the Securities Exchange Act of 1934,\nthe registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.\n\n \n\nDate: August 11, 2026\nTHERAPEUTICSMD, INC.\n\n \n \n\n \n/s/ Marlan Walker\n\n \nMarlan Walker\n\n \nChief Executive Officer\n\n \n\n \n\n2"}